A group of experts cautions that the lack of specific rules for genome-edited crops may hurt transparency, while the ...

The big pharma will spend up to $250 million over the next eight years of the collaboration. Elsewhere, CRISPR Therapeutics unveiled new data and Vivo Capital raised funds.

Imagine developing a first-of-its-kind therapy that saved the life of one woman dying from colon cancer, only to lose the financial backing needed to bring it to market. That’s the reality for ...

CRISPR Therapeutics benefits from Casgevy’s approval and a deep pipeline, despite early rollout hurdles and cost challenges.

Vienna, Austria – May 9th 2025 – Biomay, a leading manufacturer of recombinant proteins, today announced the commercial availability of its CRISPR/Cas9 nuclease, marking a significant addition to its ...